This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

C2

Claim 1 (currently amended) An oligonucleotide 8 to 50 nucleotides in length which is targeted to mRNA encoding human c-raf (SEQ ID NO: 64) and which is capable of inhibiting human c-raf expression.

Claims 2-5 (previously canceled)

Claim 6 (original): The oligonucleotide of claim 1 which has at least one phosphorothioate linkage.

Claim 7 (original): The oligonucleotide of claim 1 wherein one of the nucleotide units of the oligonucleotide is modified at the 2' position of the sugar moiety.

Claim 8 (original): The oligonucleotide of claim 7 wherein said modification at the 2' position of the sugar moiety is a 2'-o-alkyl, a 2'-o-alkyl-o-alkyl or a 2'-fluoro modification.

Claim 9 (original): The oligonucleotide of claim 1 which is a chimeric oligonucleotide.

Claim 10 (original): A composition comprising the oligonucleotide of claim 1 and a pharmaceutically acceptable carrier.

Claim 11 (original): The composition of claim 10 further comprising a chemotherapeutic agent.

Claim 12 (currently amended): A method of inhibiting the expressing of human c-raf in cells or tissues which express human c-raf comprising contacting said human cells or tissues with ~~the~~ an oligonucleotide ~~of claim 1~~ 8 to 50 nucleotides in length which is targeted to mRNA encoding human c-raf (SEQ ID NO: 64) and which is capable of inhibiting human c-raf expression.

Claim 13 (currently amended): A method of treating or preventing a condition associated with the expression of human c-raf comprising administering to a human or cells thereof a therapeutically effective amount of ~~the~~ an oligonucleotide ~~of claim 1~~ 8 to 50 nucleotides in length which is targeted to mRNA encoding human c-raf (SEQ ID NO: 64).

Claim 14 (currently amended): The method of claim 13 wherein said expression of human c-raf is abnormal expression.

Claim 15 (original): The method of claim 13 wherein said condition is a hyperproliferative condition.

Claim 16 (original): The method of claim 15 wherein said hyperproliferative condition is cancer.

Claim 17 (original): The method of claim 15 wherein said hyperproliferative condition is angiogenesis or neovascularization.

C2 cont'd

Claim 18 (original): The method of claim 17 wherein said angiogenesis or neovascularization is ocular angiogenesis or neovascularization.

Claim 19 (original): The method of claim 16 comprising administering the oligonucleotide in combination with a chemotherapeutic agent.

Claim 20 (currently amended): A method of inhibiting the hyperproliferation of cells comprising contacting hyperproliferating cells with ~~the~~ an oligonucleotide ~~of claim 1~~ 8 to 50 nucleotides in length which is targeted to mRNA encoding human c-raf (SEQ ID NO: 64).